Premium
FDG‐PET as a Biomarker of Response in DLBCL: the HOVON 84 Study Experience
Author(s) -
Burggraaff C.N.,
Vet H.C.,
Hoekstra O.S.,
Arens A.I.,
Keizer B.,
Holt B.,
Lugtenburg P.J.,
Zijlstra J.M.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_21
Subject(s) - medicine , hazard ratio , progression free survival , rituximab , clinical endpoint , nuclear medicine , log rank test , oncology , univariate analysis , clinical trial , survival analysis , overall survival , multivariate analysis , lymphoma , confidence interval